Floatz logo

Chimeric Antigen Receptor Modified T Cells Infusion

DLBCL Germinal Center B-Cell Type

Memorial Sloan Kettering Cancer CenterCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the DLBCL Germinal Center B-Cell Type cohort.

Asset / SponsorPhaseRating
Inno-206
Li Zhiming
Phase 2B
(+)-VINCRISTINE
Li Zhiming
Phase 2B
Selinexor
Li Zhiming
Phase 2CCC
Sgr-1505
Schrödinger, Inc.
Phase 1CC
MONOCLONAL ANTIBODY BC8
Memorial Sloan Kettering Cancer Center
Early Phase 1C

Same molecule, other indications

Chimeric Antigen Receptor Modified T Cells Infusion is also rated in:

B Cell LymphomaDormant
BB
Indicative ·
71 / 100
View asset →
Non Hodgkin LymphomaDormant
BB
Indicative ·
67 / 100
View asset →
B-cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →